MAPT and early-onset autosomal dominant Alzheimer disease: Can plasma phosphorylated tau 217 (p-tau217) reliably identify amyloid β (Aβ) status in cognitively unimpaired individuals for participant selection in preclinical Alzheimer disease (AD) trials or for potential future use in clinical practice?